Key Takeaways:
- The FDA warns about unapproved finasteride blends, impacting Hims & Hers Health (HIMS, Financial).
- Analysts suggest a potential 69.86% upside in HIMS stock.
- GF Value estimates indicate a fair value increase of 23.61% within a year.
The FDA has recently issued a public warning regarding the risks associated with certain unapproved topical combinations of finasteride, particularly those used in male baldness treatments. Hims & Hers Health Inc. (HIMS), known for its finasteride-minoxidil spray, could be significantly impacted by this scrutiny. The agency is investigating 32 reported cases of adverse effects, including anxiety and decreased libido, linked to these compounds.
Wall Street Analysts' Projections
Currently, based on the analysis of 15 Wall Street experts, the average one-year price target for Hims & Hers Health Inc. stands at $44.50. This projection includes a high estimate of $85.00 and a low of $22.00, reflecting a substantial potential upside of 69.86% from the present price of $26.20. For a deeper dive into these projections, visit the Hims & Hers Health Inc Forecast page.
Analysts' Recommendations
Hims & Hers Health Inc's stock is currently marked by an average brokerage recommendation of 2.7, which suggests a "Hold" status. This evaluation is part of a scale where 1 denotes a Strong Buy, and 5 indicates a Sell, offering investors a clear gauge of current market sentiment.
GuruFocus's GF Value Estimation
According to GuruFocus's estimates, the projected GF Value for Hims & Hers Health Inc in the upcoming year is $32.38. This suggests a notable potential upside of 23.61% from its current trading price of $26.195. The GF Value is meticulously calculated using the stock's historical trading multiples, past business growth patterns, and anticipated future performance. For more comprehensive insights, explore the Hims & Hers Health Inc Summary page.
